Published by Josh White on 3rd February 2022
(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.
URL: http://www.digitallook.com/dl/news/story/32438831/...